Aromatase inhibitors in breast cancer - PubMed (original) (raw)

Review

. 2003 Jun 12;348(24):2431-42.

doi: 10.1056/NEJMra023246.

Affiliations

• PMID: 12802030
• DOI: 10.1056/NEJMra023246

Review

Aromatase inhibitors in breast cancer

Ian E Smith et al. N Engl J Med. 2003.

No abstract available

PubMed Disclaimer

Comment in

• Aromatase inhibitors in breast cancer.
  Forrest AR. Forrest AR. N Engl J Med. 2003 Sep 11;349(11):1090. doi: 10.1056/NEJM200309113491117. N Engl J Med. 2003. PMID: 12968098 No abstract available.

Similar articles

• New breast cancer drug.
  Brink S. Brink S. US News World Rep. 2001 Dec 24;131(26):52. US News World Rep. 2001. PMID: 11793594 No abstract available.
• Focus on anastrozole and breast cancer.
  Mokbel K. Mokbel K. Curr Med Res Opin. 2003;19(8):683-8. doi: 10.1185/030079903125002397. Curr Med Res Opin. 2003. PMID: 14687437 Review.
• Clinical differences among the aromatase inhibitors.
  Ligibel JA, Winer EP. Ligibel JA, et al. Clin Cancer Res. 2003 Jan;9(1 Pt 2):473S-9S. Clin Cancer Res. 2003. PMID: 12538503 Review.
• Aromatase inhibitors for hormonal therapy of early-stage breast cancer.
  Traina TA, Dickler MN. Traina TA, et al. Curr Opin Investig Drugs. 2004 Jun;5(6):605-10. Curr Opin Investig Drugs. 2004. PMID: 15242248 Review.
• Aromatase inhibitors for breast cancer prevention.
  Cuzick J. Cuzick J. J Clin Oncol. 2005 Mar 10;23(8):1636-43. doi: 10.1200/JCO.2005.11.027. J Clin Oncol. 2005. PMID: 15755971 Review. No abstract available.

Cited by

• Advancements in Understanding the Hide-and-Seek Strategy of Hibernating Breast Cancer Cells and Their Implications in Oncology from a Broader Perspective: A Comprehensive Overview.
  Al-Ruwishan A, Amer B, Salem A, Abdi A, Chimpandu N, Esa A, Melemenis A, Saleem MZ, Mathew R, Gamallat Y. Al-Ruwishan A, et al. Curr Issues Mol Biol. 2024 Aug 1;46(8):8340-8367. doi: 10.3390/cimb46080492. Curr Issues Mol Biol. 2024. PMID: 39194709 Free PMC article. Review.
• Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial.
  Haddad TC, Suman VJ, Giridhar KV, Sideras K, Northfelt DW, Ernst BJ, O'Sullivan CC, Singh RJ, Desta Z, Peethambaram PP, Hobday TJ, Chumsri S, Leon-Ferre RA, Ruddy KJ, Yadav S, Taraba JL, Goodnature B, Goetz MP, Wang L, Ingle JN. Haddad TC, et al. Clin Cancer Res. 2024 Aug 1;30(15):3147-3156. doi: 10.1158/1078-0432.CCR-24-0341. Clin Cancer Res. 2024. PMID: 38752717 Free PMC article. Clinical Trial.
• Endothelial dysfunction in breast cancer survivors on aromatase inhibitors: changes over time.
  Shaaban A, Petersen A, Beckwith H, Florea N, Potter DA, Yee D, Vogel RI, Duprez D, Blaes AH. Shaaban A, et al. Cardiooncology. 2024 May 1;10(1):27. doi: 10.1186/s40959-024-00227-z. Cardiooncology. 2024. PMID: 38693561 Free PMC article.
• Vaginal microbiomes of breast cancer survivors treated with aromatase inhibitors with and without vulvovaginal symptoms.
  Prasanchit P, Pongchaikul P, Lertsittichai P, Tantitham C, Manonai J. Prasanchit P, et al. Sci Rep. 2024 Mar 28;14(1):7417. doi: 10.1038/s41598-024-58118-3. Sci Rep. 2024. PMID: 38548910 Free PMC article.
• Bibliometric analysis and visualization of endocrine therapy for breast cancer research in the last two decade.
  Wang D, Yang Y, Yang L, Yang H. Wang D, et al. Front Endocrinol (Lausanne). 2023 Dec 5;14:1287101. doi: 10.3389/fendo.2023.1287101. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38116321 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information